Basel, Switzerland – Clinerion announces new services for market access which give pharmaceutical companies insight into patient populations based on its health data analytics tools.
Clinerion’s Patient Recruitment System (PRS) Patient Finder tool has a wealth of health data which can now be harnessed to guide pharmaceutical companies in their R&D and commercial decision making by providing information on the prevalence of target diseases and the distribution of patient populations.
Market access is becoming an integral part of not only the commercial activities of a pharmaceutical company, but of the whole value chain, including the R&D process. As the market further matures and competition for patients increases, having a registered drug on the market is no longer a measure of success, but only an intermediate step towards success on the market. The availability of solid data to back up decision making becomes vital in ensuring the commercial future of a drug, and having real-time data becomes indispensable to market access experts.
Fully anonymized, aggregated data, sourced from the expanding network of hospitals covered by Clinerion’s PRS, can provide answers to a number of questions. Disease prevalence can be monitored with a precision never before possible, with daily updates on new cases. The financial analysis of the cost of treatments can be performed based on real data, rather than empirical interviews with physicians.
“As we venture into healthcare data analytics, we see a growing demand from pharma companies”, says Tigran Arzumanov, Head of Sales of Clinerion. “With the expansion of our global footprint, we find ourselves in geographies previously not covered by any data collection platforms. There is no substitute for data as far as market access decisions are concerned – and our technology provides a straightforward, easy way to tap into electronic health record (EHR) data globally, regardless of the EHR platform or coding conventions used.”
About Clinerion
Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Recruitment System accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Key tools for Clinerion’s patient data services include data-assisted protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and cost savings by streamlining operations and gaining strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology company headquartered in Switzerland. Clinerion's solutions follow international patient privacy and data security standards.
Clinerion website: www.clinerion.com
Clinerion’s Patient Recruitment System: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.